

EFORT Head Office
ZA La Pièce 2
1180 Rolle, Switzerland
Tel +41 21 343 44 00
Fax +41 21 343 44 11
office@efort.org

www.efort.org



EFORT Statement on Cobalt in Orthopaedic implants

*Update from the earlier **Joint Statement of EFORT and MedTech Europe's Orthopaedic Sector Group 14 August 2018***

The EU Commission will, after receiving guidance from the ECHA on October 1 2021, raise the concern level for Cobalt contained in medical devices. The latter has been discussed for a long period, resulting in the EFORT - MedTech Statement of August 2018. The concerns have arisen mainly in patients with metal-on-metal bearing joint replacements. Although the presence of cobalt and other metals, such as chromium, in orthopaedic implants generates conflicting evidence related to potentially hazardous effects in patients, EFORT takes this potential very seriously. Therefore, EFORT has taken the decision to perform clinical research on all available evidence within its "Implant & Patient Safety Initiative (IPSI)". We will keep you informed of our findings, but please feel free to contact us for information on the topic.

"Science is leading for better patient outcome".

PRESIDENT

Prof. Dr. Li Felländer-Tsai
li.fellander-tsai@efort.org

FIRST VICE PRESIDENT

Prof. Dr. Enrique Gómez Barrena
enrique.gomezbarrena@efort.org

SECOND VICE PRESIDENT

Mr. David Limb
david.limb@efort.org

SECRETARY GENERAL

Prof. Dr. Rob Nelissen
rob.nelissen@efort.org

PAST PRESIDENT

Prof. Dr. Klaus-Peter Günther
klaus-peter.guenther@efort.org

TREASURER

Prof. Dr. Theofilos Karachalios
theofilos.karachalios@efort.org

MEMBER

Dr. Katre Maasalu
katre.maasalu@efort.org

MEMBER

Prof. Dr. Stefan Nehrer
stefan.nehrer@efort.org

MEMBER

Prof. Dr. Pietro Ruggieri
pietro.ruggieri@efort.org

YOUNG MEMBER

Dr. Filipe Lima Santos
filipe.lima.santos@efort.org